Revance Stock In The News

RVNC Stock  USD 3.73  0.11  2.86%   
Our overall analysis of Revance's news coverage and content from conventional and social sources shows investors' bearish mood towards Revance. The specific impact of Revance news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Revance's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Revance headlines in addition to utilizing other, more conventional financial analysis modules. Check out Revance Backtesting and Revance Hype Analysis.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.

Revance Today Top News and Investor Outlook

Yahoo News
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
https://finance.yahoo.com/news/100-club-piper-sandler-3-005047923.html
 Bullish
Yahoo News
Shareholders in Revance Therapeutics (NASDAQ:RVNC) are in the red if they invested a year ago
https://finance.yahoo.com/news/shareholders-revance-therapeutics-nasdaq-rvnc-120543548.html
 Bullish
Yahoo News
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
https://finance.yahoo.com/news/aesthetics-market-resilience-abbvie-asserts-153101947.html
 Bullish
Yahoo News
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
https://finance.yahoo.com/news/revance-provides-corporate-preliminary-fourth-130000139.html
 Bullish
Yahoo News
Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers
https://finance.yahoo.com/news/analysts-just-slashed-revance-therapeutics-100652943.html
 Neutral
Yahoo News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript
https://finance.yahoo.com/news/revance-therapeutics-inc-nasdaq-rvnc-000519005.html
 Bullish
Yahoo News
Q3 2023 Revance Therapeutics Inc Earnings Call
https://finance.yahoo.com/news/q3-2023-revance-therapeutics-inc-145433069.html
 Bullish
Yahoo News
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
https://finance.yahoo.com/news/revance-therapeutics-inc-rvnc-reports-000006855.html
 Bullish
Yahoo News
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
https://finance.yahoo.com/news/revance-reports-third-quarter-2023-210600775.html
 Bullish
Yahoo News
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
https://finance.yahoo.com/news/revance-appoints-erica-jordan-chief-210500859.html
 Bullish

Revance Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Revance and other traded companies coverage with news coverage. We help investors stay connected with Revance headlines for the 25th of November to make an informed investment decision based on correlating the impacts of news items on Revance Stock performance. Please note that trading solely based on the Revance hype is not for everyone as timely availability and quick action are needed to avoid losses.
Revance's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Revance investors visualize upcoming and past events in order to time the market based on Revance noise-free hype analysis.
Revance stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Revance earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Revance that are available to investors today. That information is available publicly through Revance media outlets and privately through word of mouth or via Revance internal channels. However, regardless of the origin, that massive amount of Revance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Revance news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Revance relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Revance's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Revance alpha.

Revance Largest EPS Surprises

Earnings surprises can significantly impact Revance's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-05-13
2015-03-31-0.73-0.650.0810 
2014-11-12
2014-09-30-0.68-0.60.0811 
2017-05-09
2017-03-31-0.85-0.94-0.0910 
2024-02-28
2023-12-31-0.72-0.620.113 
2022-05-10
2022-03-31-0.83-0.94-0.1113 
2017-02-27
2016-12-31-0.84-0.95-0.1113 
View All Earnings Estimates

Revance Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Revance Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
21st of November 2024
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
at MacroaxisInsider 
seekingalpha News
19th of November 2024
Revance Therapeutics stock gains as Crown Labs further extends tender offer
at seekingalpha.com 
Macroaxis News
14th of November 2024
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
at MacroaxisInsider 
seekingalpha News
12th of November 2024
Revance Therapeutics jumps after Crown Laboratories tender offer extended again
at seekingalpha.com 
news
11th of November 2024
Shareholders that lost money on Revance Therapeutics, Inc. should contact Levi Korsinsky a...
at accesswire.com 
news
8th of November 2024
Levi Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. Re...
at accesswire.com 
Yahoo News
7th of November 2024
Revance Therapeutics, Inc. Reports Q3 Loss, Lags Revenue Estimates
at finance.yahoo.com 
Macroaxis News
24th of October 2024
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
9th of October 2024
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
at MacroaxisInsider 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Revance in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Revance's short interest history, or implied volatility extrapolated from Revance options trading.
When determining whether Revance offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Revance's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Revance Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Revance Stock:
Check out Revance Backtesting and Revance Hype Analysis.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.34)
Revenue Per Share
2.656
Quarterly Revenue Growth
0.107
Return On Assets
(0.24)
Return On Equity
(20.97)
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.